依帕司他联合甲钴胺治疗糖尿病周围神经病变的临床疗效

Clinical effect of epalrestat combined with methycobal in the treatment of diabetic peripheral neuropathy

目的探讨依帕司他联合甲钴胺治疗糖尿病周围神经病变的临床疗效。方法选取2016年6月至2017年6月我院收治的78例糖尿病周围神经病变患者为研究对象,随机分为常规组与研究组,各39例。常规组患者给予甲钴胺治疗,研究组患者在常规组治疗基础之上给予依帕司他。比较两组患者的临床效果。结果研究组患者治疗总有效率为92.30%,明显高于常规组的76.93%,差异具有统计学意义(P<0.05)。治疗前,两组患者的MNCV及SNCV比较,差异无统计学意义(P>0.05);治疗后,两组患者的MNCV及SNCV明显优于治疗前,且研究组明显优于常规组(P<0.05)。两组患者的不良反应发生率比较,差异无统计学意义(P>0.05)。结论应用依帕司他联合甲钴胺治疗糖尿病周围神经病变可获得满意的临床疗效,可使患者的神经传导速度得到显著改善,不良反应较轻,值得临床推广应用。

Objective To explore the clinical effect of epalrestat combined with methycobal in the treatment of diabetic peripheral neuropathy. Methods Seventy-eight diabetic peripheral neuropathy patients admitted in our hospital from June2016 to June 2017 were selected and randomly divided into routine group and study group, with 39 cases in each group. The routine group was treated with methycobal, and the study group was given epalrestat combined with methycobal. The clinical effects of the two groups were compared. Results The total effective rate of the study group was 92.30%, which was higher than 76.93% of the routine group, the difference was statistically significant（P〈0.05）. Before treatment, there were no significant differences in the MNCV and SNCV between the two groups（P〉0.05）; after treatment, the MNCV and SNCV of the two groups were better than those before treatment, and those of the study group were better than the routine group（P〈0.05）. There was no significant differences in adverse reaction rate between the two groups（P〉0.05）. Conclusion Epalrestat combined with methycobal in the treatment of diabetic peripheral neuropathy can achieve satisfactory clinical effect, it can obviously improve the nerve conduction speed, and the adverse reaction is mild, which is worthy of clinical application and promotion.